Black Rock Inc. Oyster Point Pharma, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$7.95 - $11.68 $3.99 Million - $5.87 Million	-502,288 Reduced 99.59%	2,085 $23,000
Q3 2022 Nov 14, 2022	SELL	$4.41 - $8.38 $127,497 - $242,274	-28,911 Reduced 5.42%	504,373 $2.83 Million
Q2 2022 Aug 12, 2022	SELL	$3.6 - $11.2 $2.01 Million - $6.26 Million	-558,550 Reduced 51.16%	533,284 $2.31 Million
Q1 2022 May 12, 2022	SELL	$8.58 - $17.65 $288,974 - $594,452	-33,680 Reduced 2.99%	1,091,834 $12.7 Million
Q4 2021 Feb 10, 2022	BUY	$10.17 - $18.96 $969,648 - $1.81 Million	95,344 Added 9.26%	1,125,514 $20.6 Million
Q3 2021 Nov 09, 2021	BUY	$11.67 - $18.07 $601,028 - $930,641	51,502 Added 5.26%	1,030,170 $12.2 Million
Q2 2021 Aug 11, 2021	BUY	$16.25 - $21.51 $15.9 Million - $21.1 Million	978,668 New	978,668 $16.8 Million

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.